Nerve Block — Cost, Top Hospitals & Success Rates | MyMedicPlus

A nerve block is an interventional pain procedure in which a solution — local anaesthetic, corticosteroid, neurolytic agent (phenol, alcohol, glycerol), or a combination — is injected near a specific nerve or nerve plexus to interrupt pain signal transmission. Nerve blocks are classified by duration and mechanism: diagnostic blocks (short-acting local anaesthetic to confirm the pain source); therapeutic blocks (local anaesthetic plus corticosteroid for temporary pain relief and reduction of inflammation); prognostic blocks (to predict the response to ablative procedures); neurolytic blocks (phenol or alcohol to permanently or semi-permanently destroy nerve tissue — used for cancer pain or essential tremor). Guidance modalities ensure accurate needle placement: ultrasound-guided nerve blocks are the current standard for peripheral nerve and plexus blocks, enabling real-time needle visualisation and reducing complication rates; fluoroscopy (X-ray guidance) is used for epidural, spinal facet, and sympathetic blocks; CT guidance is used for deep blocks such as coeliac plexus and splanchnic nerve blocks. Nerve blocks are performed in a sterile procedural suite by pain anaesthesiologists or interventional pain specialists. Common peripheral nerve blocks include femoral, sciatic, brachial plexus, intercostal, and occipital nerve blocks. Neuraxial blocks include epidural, intrathecal, and spinal. Sympathetic blocks target the stellate ganglion, coeliac plexus, lumbar sympathetic chain, and ganglion impar.

Nerve blocks are used across a wide spectrum of acute and chronic pain conditions: acute pain — regional anaesthesia for surgical procedures (interscalene block for shoulder surgery, femoral and sciatic nerve blocks for knee and hip surgery, TAP block for abdominal surgery, paravertebral block for thoracic surgery) reduces opioid requirements, accelerates recovery, and improves post-operative analgesia. Post-operative pain and rib fracture pain (intercostal nerve block). Chronic pain — facet joint blocks and medial branch blocks for lumbar and cervical facet arthropathy; epidural steroid injections for radiculopathy from disc herniation or spinal stenosis; selective nerve root blocks for diagnostic and therapeutic use in radiculopathy. Neuropathic pain — stellate ganglion block for CRPS of the upper extremity; lumbar sympathetic block for CRPS of the lower extremity; occipital nerve block for occipital neuralgia and cluster headache. Cancer pain — coeliac plexus neurolysis for pancreatic and upper abdominal cancer pain (70–90% pain relief); superior hypogastric plexus block for pelvic cancer pain; intercostal nerve cryoablation for mesothelioma or rib metastasis. Peripheral neuropathic pain — trigeminal ganglion block for trigeminal neuralgia; pudendal nerve block for vulvodynia and chronic pelvic pain. Headache — greater occipital nerve block and sphenopalatine ganglion block for migraine and cluster headache.

Eligibility for a nerve block depends on the indication, patient's medical status, anticoagulation, and the anatomical target. For diagnostic and therapeutic nerve blocks: patients must have pain corresponding to the distribution of the target nerve or plexus; be able to provide informed consent; not have active infection at the injection site; not have a documented allergy to local anaesthetic agents (rare). Anticoagulation management varies by block site — peripheral nerve blocks carry low bleeding risk and can often proceed with therapeutic anticoagulation; neuraxial blocks (epidural, intrathecal) require anticoagulation to be held according to ASRA guidelines (e.g., warfarin held until INR below 1.5; LMWH held 12–24 hours before; direct oral anticoagulants held 24–48 hours). Neurolytic blocks (coeliac plexus neurolysis) are reserved for cancer pain patients with limited life expectancy in whom permanent neurological effects are acceptable trade-offs for superior pain control. Pregnancy is a relative contraindication to corticosteroid injections. Pre-procedure assessment includes review of imaging, neurological examination, coagulation status, allergy history, and current medications. Ultrasound assessment of target anatomy is performed at the start of the procedure.

Treatment options are tailored to individual patient needs based on disease severity, comorbidities, patient preference, and clinical guidelines. The treating physician will discuss all available options and recommend an approach based on the complete clinical assessment.

First-line treatment follows established evidence-based protocols with well-documented efficacy and safety profiles. This may involve pharmacological therapy with single or combination agents, procedural intervention using minimally invasive or open techniques, or a combination approach integrating multiple treatment modalities.

Second-line options are considered when primary treatment fails to achieve therapeutic targets or is not tolerated. These include alternative agents within the same drug class, different treatment modalities, or escalation to more intensive therapy at specialist centres.

Emerging treatments available through clinical trials or specialist referral include novel targeted agents, biological therapies, advanced procedural techniques, and gene therapy approaches for selected conditions. Patients are encouraged to discuss eligibility for clinical trials with their specialist. Treatment intensity is regularly reassessed and adjusted based on clinical response, ensuring optimal outcomes while minimising unnecessary exposure to treatment-related risks.

The selection of treatment approach follows a systematic assessment of clinical factors, patient preferences, and risk-benefit considerations. Evidence-based guidelines from professional societies including WHO, NICE, and relevant specialty organisations inform treatment selection and protocol design.

Combination treatment strategies are increasingly favoured where multiple modalities provide synergistic benefit. The sequence and intensity of treatment components are titrated based on patient response at defined assessment intervals. Patients not responding adequately to initial treatment undergo structured reassessment to identify alternative approaches or combination strategies.

Personalised medicine approaches using biomarker profiling and genetic analysis are emerging as tools to predict treatment response and guide individualised treatment selection in eligible patients. Multidisciplinary team review ensures all relevant clinical expertise informs treatment decisions for complex cases.

Regional nerve blocks provide superior analgesia with minimal systemic opioid use — the cornerstone of Enhanced Recovery After Surgery (ERAS) protocols. Interscalene brachial plexus block for shoulder surgery reduces post-operative opioid consumption by 60–80% in the first 24 hours, reduces pain scores, and enables same-day or next-day discharge. Femoral nerve block after total knee replacement halves opioid requirements and enables earlier physiotherapy. Epidural steroid injection provides 60–75% of radiculopathy patients with 4–12 weeks of significant leg pain relief, enabling physiotherapy participation. Facet joint medial branch blocks confirm facet arthropathy and direct radiofrequency ablation, which provides 50–80% pain reduction lasting 12–24 months in 60–70% of treated patients. Coeliac plexus neurolysis for pancreatic cancer reduces pain scores by 70–90%, reduces opioid requirements by 40–50%, and prolongs survival in randomised trials (possibly by reducing stress and opioid-related immunosuppression). Occipital nerve block reduces migraine and occipital neuralgia frequency by 50–70% for 4–12 weeks. Stellate ganglion block for CRPS produces complete or partial remission in 40–70% of upper limb CRPS cases, particularly when performed early in the disease course.

Nerve block complications vary by anatomical location and technique. Common minor risks include: transient post-procedure pain ('post-injection flare') lasting 24–48 hours; injection site bruising and swelling; temporary increase in blood glucose (from corticosteroid in diabetic patients); numbness or motor weakness in the distribution of the blocked nerve (expected with local anaesthetic blocks, resolves within hours). Less common risks: inadvertent intravascular injection of local anaesthetic causing systemic local anaesthetic toxicity (LAST) — manifesting as arrhythmia, cardiovascular collapse, or seizures (0.01–0.1%); managed with lipid emulsion (Intralipid). Epidural steroid risks include: post-dural puncture headache from inadvertent dural puncture (1–3%); epidural haematoma causing spinal cord compression (extremely rare, <1:150,000 — requires emergency decompression); and epidural infection (extremely rare). Pneumothorax risk with intercostal and supraclavicular brachial plexus blocks (1–4% without ultrasound guidance; <0.5% with). Phrenic nerve block causing hemidiaphragm paresis with interscalene blocks (100% incidence — contraindicated in patients with contralateral phrenic nerve palsy or severe lung disease). Neurolytic blocks — permanent neurological injury including motor weakness, deafferentation pain, and bowel/bladder dysfunction — are irreversible and only appropriate for cancer pain. Infection (abscess) at injection site — extremely rare with sterile technique.

Structured follow-up is essential to optimise treatment outcomes and ensure early identification of complications or disease recurrence. The follow-up schedule is individuialised based on treatment type, disease characteristics, and patient-specific factors.

Standard follow-up scheduling involves: early post-treatment review at 2-4 weeks to assess initial response and manage any early side effects; monthly assessments for the first 3 months to monitor treatment response and titrate therapy as needed; quarterly review for the remainder of the first year; and annual long-term follow-up for stable patients.

Each follow-up visit includes clinical examination, relevant laboratory testing as indicated by the treatment protocol, imaging studies at defined intervals based on condition-specific guidelines, and assessment of patient-reported outcomes and quality of life.

Patients are provided with clear guidance on symptoms requiring urgent medical review between scheduled appointments, including signs of serious complications or disease progression. Remote consultation options including telephone and video review facilitate access to specialist advice between face-to-face appointments. Long-term surveillance continues indefinitely for chronic conditions, with frequency adjusted based on individual risk profile and clinical response.

Nerve block procedures in India are 60–80% cheaper than comparable procedures in the USA. Ultrasound-guided peripheral nerve block (e.g., femoral, sciatic, intercostal) for surgical anaesthesia or post-operative pain: USD 150–400. Epidural steroid injection (lumbar or cervical, fluoroscopy-guided): USD 200–600. Facet joint injection or medial branch block (lumbar or cervical): USD 250–700. Greater occipital nerve block: USD 100–300. Coeliac plexus neurolysis (CT-guided, for cancer pain): USD 500–1,500. Stellate ganglion block: USD 300–800. Sphenopalatine ganglion block: USD 200–500. These procedures are available at pain management departments of leading Indian hospitals (Apollo, Fortis, Medanta, Manipal, Amrita, AIIMS). In the USA, a fluoroscopy-guided epidural steroid injection costs USD 3,000–8,000; coeliac plexus neurolysis USD 5,000–15,000. UK private nerve block procedures cost GBP 500–2,500 depending on complexity. International patients travelling to India for cancer pain nerve blocks or complex chronic pain procedures achieve very significant cost savings while accessing experienced interventional pain specialists with international fellowship training.

Alternative treatment approaches are considered when first-line treatment is contraindicated, not tolerated, or fails to achieve therapeutic targets. The range of alternatives depends on the specific condition and patient circumstances.

Conservative management with watchful waiting and close monitoring is appropriate for mild or asymptomatic presentations where the natural history is favourable and intervention risks outweigh expected benefits. Regular surveillance allows timely escalation when clinical criteria for active treatment are met.

Non-pharmacological approaches including physiotherapy, occupational therapy, dietary optimisation, and structured lifestyle modification programmes form the foundation of management for many conditions. These interventions reduce symptom burden, improve functional capacity, and may delay or eliminate the need for pharmacological or procedural treatment.

Alternative pharmacological approaches include agents from different drug classes with different mechanisms of action, dosing strategies, or delivery routes. Clinical trials evaluating novel agents may offer access to emerging therapies not yet in routine clinical practice.

Surgical alternatives range from minimally invasive endoscopic or laparoscopic approaches to open surgery, each appropriate for different clinical scenarios. Complementary and integrative medicine approaches including acupuncture, herbal medicine, and mind-body therapies may provide symptomatic benefit for some patients as adjuncts to conventional care, though evidence quality varies and potential interactions with conventional treatment should be discussed with a qualified practitioner.